Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
YKRH00020 Inhalation Solution for Adult Lower Respiratory Tract Infection With Viscous Sputum
CTR20263095Phase 2Active
- Sponsor
- Beijing Yingkairui Drug Research
- Start
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of YKRH-00020 in chronic bronchitis (CB), chronic obstructive pulmonary disease (COPD), pneumonia and 1 more (3 arms), sponsored by Beijing Yingkairui Drug Research. Primary endpoint: Change in sputum consistency score from baseline at end of treatment. Started Aug 2026; status: active.
02
Drugs
YKRH-00020
03
Conditions
chronic bronchitis (CB)chronic obstructive pulmonary disease (COPD)pneumoniabronchiectasis
Beyond the preview
Go deeper on CTR20263095.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263095.